Biomarkers Global Market Size Scope of the Study This report gives an insight into different types of biomarkers and their impact on various disease areas such as oncology, cardiology, neurology, infectious diseases, genetic disorders, and other areas Autoimmune, Endocrine, Hematological, Nutritional Deficiencies, Hepatic, Renal, and Bone related Diseases. The market is further divided by various therapeutic areas such as - Prostate Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer and Other for Oncology segment; Coronary Heart Diseases, Heart Failure, Myocardial Infarction and Other for Cardiology, Neurodegenerative Diseases, Stroke, Brain Tumor and Other for Neurology segment; and Viral Infections, Tuberculosis and Other for Infectious diseases. The study provides global market analysis for biomarkers by the above disease areas and also by prominent biomarker Identification technologies including imaging, genomics, proteomics, metabolomics, gene expression and other technologies comprising fluorescent indicators, lab-on-chip, nuclear magnetic resonance, mass spectrometry/liquid chromatography and nanobiotechnology. Though the report mentions nonmedical applications of biomarkers, the study emphasizes only on medical applications. The study includes estimates and projections for the total global biomarkers market. The market covered for genomics, proteomics and gene expression pertains only to biomarker Identification applications. Projections and estimates are also illustrated by geographic regions encompassing the North America, Europe, Asia-Pacific, and Rest of World (RoW). Business profiles of 106 major companies are discussed in the report. The report serves as a guide to global biomarker industry, as it covers more than 626 companies that are engaged in biomarkers R&D, discovery, testing and supply of products and services. Major Contract Research Organizations and Universities serving biomarkers industry are also covered in the Corporate Directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report. The Biomarkers report is an ideal research tool providing strategic business intelligence to the corporate sector. This report may help strategists, investors, laboratories, pharmaceutical companies, contract research organizations, biotechnology companies and drug approval authorities in- Gauging Competitive Intelligence Identifying Key Growth Areas and Opportunities Understanding Geographic Relevance to Product Knowing Regional Market Sizes and Growth Opportunities and Restraints
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 1
Keeping Tab on Emerging Technologies Equity Analysis Tapping New Markets
Analytics and data presented in this report pertain to several parameters such as – Global And Regional Market Sizes, Market Shares, Market Trends Product (Global And Regional) Market Sizes, Market Shares, Market Trends Technology Trends Corporate Intelligence Key Companies By Sales, Brands, Products Consumer Behavioral Patterns Other Strategic Business Affecting Data
Research Methodology RI Technologies publishes business intelligence reports by going through a cycle of diligent research and analysis activity. Research is done using both online and offline resources. The study outline of this report is sketched on the following lines – global market analysis, regional market analysis, product segmentation, global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape, technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is also helpful for making market evaluations, and estimating the market size for the future. This report is uniquely researched and the methodology includes: Scope of Study Product Definitions Segmental Analysis Regional Analysis Exclusive Data Analytics Corporate Intelligence Feedback
Right from concept to final compilation of this report, both primary and secondary research methods are applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the information for authentication of our own findings.
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 2
Secondary research includes government publications, investment research reports, web based surveys, website information of both companies and markets, and other offline resources such as print publications and CDs. Our compilation of easy to navigate PDF reports are essential value addition resources for leading and growing companies.
RITMIR003: Biomarkers – A Market Insight Report, July 2013 Š RI Technologies - www.researchimpact.com
Sample Page - 3
II. REPORT SYNOPSIS
Biomarkers Biomarker is a body constituent that identifies the cause and vulnerability to certain diseases. Biomarkers can be broadly divided into the following two groups
Biomarkers of Exposure – Usually applied for forecasting risks.
Therapeutic Biomarkers – Employed for analyzing, detecting and curing various diseases.
Biomarker can also be defined as the traits (biological, pathogenic, or pharmacological responses given out by a patient to therapeutics) exhibited by a patient. Biomarkers identification is fast gaining importance, especially in the field of medical research. Latest innovations in the area of transcriptomics, proteomics and metabolomics are driving the trend. Despite Systems Biology providing a better description and understanding of disease pathologies, biomarker identification continues to face challenges. Describing the dynamic range of proteins in plasma is a crucial problem for biomarker identification. Human plasma is the easiest source for disease biomarker identification. The complexity and the wide dynamic range in protein concentrations of human plasma, makes it difficult to characterize as a potential biomarker identification and validation candidate. This report analyzes the following biomarker identification technologies and therapeutic areas in which biomarkers find applications. Synopsis chapter of the report gives a summary of biomarkers segmented by identification technologies and by therapeutic areas at global level and for each geographic region - North America, Europe, AsiaPacific and Rest of World (RoW).
Segmentation of Biomarkers Exhibit 1. Segmentation of Global Biomarkers Market by Therapeutic Area and Identification Technology
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 4
Exhibit 2. Segmentation by Therapeutic Area for Oncology, Cardiology, Neurology, and Infectious Diseases
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 5
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 6
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 7
Global Market Analysis Global biomarkers market is projected to reach about US$ XX.XX billion by 2020 from US$ XX.XX billion in 2012, registering a compounded annual growth rate (CAGR) of XX.XX % during the period 2005-2020. Exhibit 3. Biomarkers – Global Value Market Estimations and Predictions (2005-2020) in US$ Billion
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 8
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 9
Breast Cancer Biomarkers
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 10
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 11
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 12
Exhibit 4. Imaging Technologies for Biomarker Identification – Global Value Market Estimations and Predictions (2005-2020) in US$ Million for North America, Europe, Asia-Pacific and Rest of World
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 13
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 14
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 15
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 16
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 17
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 18
BIOMARKERS - OUTLOOK Global Biomarkers market is projected to grow at 21.8% compounded annually from 2005 through 2020. This growth would be driven mainly by integration of biomarkers into clinical trials. Biomarkers are expected to increase productivity by identifying potential drug failures in initial stages, leading to savings in time and costs.
Biomarkers are becoming an essential part of drug discovery process, bolstering efficiency and accuracy. The United States (with 40% of global market share in 2008) is the world’s largest regional market. Due to the cost advantage and access to the latest technology, Asia-Pacific is expected to emerge as the fastest growing (XX.XX% during 2005-2020) market for biomarkers……
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 19
IV. PRODUCT/TECHNOLOGY RESEARCH Biomarkers are indicators of biologic processes. They simplify pharmaceutical development processes by measuring biological, pharmacological and therapeutic responses of the human body. The potential of biomarkers is immense ranging from applications in medical fields to industrial areas. The need for biomarkers was realized almost 50 years back and since then this field remained in the limelight. Genes, metabolites and proteins indicate the biological condition of the human system. Along with conventional techniques including imaging, genomics and proteomics, various types of markers are identified using high throughput technologies such as gene microarrays and metabolite NMR. Leading biotechnology and pharmaceutical players are collaborating to develop innovative biomarker identification technologies using mass spectrometry and NMR data. Various data analysis challenges such as process related artifacts, inter-individual variability, and huge amount of data makes the present automated metabolite marker discovery process complicated. Thus, the process of biomarker identification is still predominantly manual that requires years of experience in the fields of biology, mathematics, and advanced experimental technologies. Biomarkers can also be defined as elements in blood, cells tissues or body fluids. A rise in the level of biomarkers indicates the presence of certain type of cancer or abnormal growth in the body. Some of the common biomarkers include CA 125, CA 15-3, and CEA PSA that deal with ovarian cancer, breast cancer, and cancers related to gastro intestine and prostate gland. These are also termed as tumor markers. In the broader context, biomarkers can be termed as elements that indicate the state of a living cell or organism. For instance, Rubidium chloride is used to analyze perfusion of heart tissues. Biomarkers are used to identify and isolate cells in cell biology. Various cell varieties are isolated to study and genetically modify plants to develop the desired traits. Biomarkers also study the spread of various epidemics and pollution resulting from toxic gases. In such cases, a biomarker is usually an external element or a substance that controls metabolic activities. Biomarkers are termed as genetic markers since they are also used to sample DNA to detect symptoms, causes of diseases and their vulnerability. Biomarkers are termed as bio signatures in the fields of geology and astrobiology. This science also finds application in the discovery of petroleum from the earth’s crust.
RITMIR003: Biomarkers – A Market Insight Report, July 2013 Š RI Technologies - www.researchimpact.com
Sample Page - 20
Exhibit 5. List of FDA Approved and Potential Serum Biomarkers for Various Diseases
About RI Technologies RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging technologies in areas of discovery, design and development.
Research – As Good as the Methodology is!
Gauging Competitive Intelligence
Identifying Key Growth Areas and Opportunities
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 21
Understanding Geographic Relevance to Product
Knowing Regional Market Sizes and Growth Opportunities and Restraints
Keeping Tab on Emerging Technologies
Equity Analysis
Tapping New Markets
© COPYRIGHT The copyright and publication rights to all RI Technologies' reports and other products are the property of the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of the material without express permission is not allowed. The buyer, under no circumstances, shall license, resell or repackage, or sell data without prior permission of the company.
DISCLAIMER RI Technologies sells content in good faith. The company is not liable to the buyer for any implications arising out of the usage of data for any particular purpose. The company makes no representations or warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for data compilation and presentation, the company does not accept any responsibility for findings in the study which are a cumulative effort of primary and secondary research resources. The studies do not endorse or promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage of the data.
RITMIR003: Biomarkers – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com
Sample Page - 22